Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lucitanib

A novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. Lucitanib inhibits VEGFR-1, -2, -3 and FGFR-1, -2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and FGFRs belong to the family of receptor tyrosine kinases that may be upregulated in various tumor cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	VEGFR/FGFR dual kinase inhibitor E-3810
Code name:	AL3810 E-3810
Chemical structure:	1-naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-

lucitanib

Search NCI's Drug Dictionary